Cell and gene therapy
Cell and gene therapy makes medicines that add, repair or switch off genes in a patient's cells, or that are themselves living cells, often the patient's own, changed in a lab and given back.
1990
On 14 September 1990 researchers at the US National Institutes of Health (NIH) began the first clinical trial of gene therapy, adding a working ADA gene to the white blood cells of a 4-year-old girl with an inherited immune disease, ADA-SCID.
25
Milestones achieved across 4 domains.
9
To watch for: announced, not yet confirmed outside.
8
Open deliverables. Nobody has shipped them.
In one minute
Where it started
Cell therapy grew out of bone marrow transplants: in 1968 teams in Minnesota and Wisconsin moved marrow between matched brothers and sisters. Gene therapy began in 1990, when NIH researchers added a working gene to a child's immune cells, the same year Steven Rosenberg's team reported tracking gene-marked cells in people. In 1989 a lab in Israel built the chimeric antigen receptor, the design behind today's CAR-T cancer medicines.
Where it stands
On 30 October 2026 the FDA's list of approved cell and gene therapy products had 55 entries, from cord-blood stem cells to CAR-T cells and one-time gene therapies. Single doses are priced in the millions of dollars, and some approved products have been withdrawn because too few patients or payers took them up. Regulators now accept smaller studies for very rare diseases, while FDA officials have asked new CAR-T medicines to beat existing treatment in randomised trials.
What is open
Much of what the field knows sits in scattered papers, company filings and review documents: how long patients wait for a dose, how often making one fails, which trials were stopped and why, what each approval rested on, and which payment deals exist. Each could become an open, checked table built from public sources, with an AI model drafting entries and a person checking them. Where these treatments can be given is mapped for parts of the US and England only; by the World Health Organization's count about 515,000 babies are born with sickle cell disease each year, about 80% of them in sub-Saharan Africa, where a Nigerian patient leader told SciDev.Net in 2026 that gene therapy "exists only on paper".
Domains
AchievedWatch forOpen
Domain
Progress
Last achieved
Watch for
Open
Living cell medicines
This work makes medicines from living cells, taken from the patient or from a donor, often changed so that they find and attack a chosen target.
7 · 2 · 2
Last achievedDonor stromal cells approved2024
Watch forFirst CAR-T for autoimmunity
2
openMaking each dose
This work turns a patient's or a donor's cells into a dose that passes its release tests, and gets it back to the patient in time.
5 · 2 · 2
Last achievedPoint-of-care manufacturing becomes law2025
Watch forCAR-T made in two days
2
openTesting and approval
This work tests cell and gene therapies in people and decides, through regulators, whether they may be sold and on what evidence.
6 · 3 · 2
Last achievedEarly approval taken back2024
Watch forApproval on one study
2
openPaying and reaching patients
This work sets prices for treatments given once that cost hundreds of thousands to millions of dollars, finds ways for health systems to pay for them, and gets patients to the few centres that can give them.
7 · 2 · 2
Last achievedOne negotiator for many states2025
Watch forThe CMS model widens
2
open
Advances to build with
1 research note
Open in cell and gene therapy
3 of 8 open deliverables
Open · Living cell medicines
CAR-T trials and their results
A free, downloadable table with one row per registered CAR-T or CAR-NK trial, giving the target, the disease, whether the cells are the patient's or a donor's, the receptor's signalling parts where they are reported, the country, the trial's status, and a link to any posted or published result, or "none found". The table refreshes monthly.
Built with what exists
The ClinicalTrials.gov API (version 2) and the Chinese and EU trial registries; the Europe PMC API for papers; a large language model such as Claude to draft each row from the papers, with a person checking every field against its source. The note "Findings that cite notes" covers an agent that cites the source behind each finding, the habit this table needs.
Open · Making each dose
A public vein-to-vein table
A free table of vein-to-vein time, the days from collecting a patient's cells to infusing the finished dose, for every approved CAR-T and T-cell product. Each row gives product, disease, country, year, the median reported, the exact definition the source used, and a link.
Built with what exists
The Europe PMC and ClinicalTrials.gov APIs; FDA and EMA product documents read with pdftotext; a large language model such as Claude to find candidate figures, with a person confirming each one; a CSV in a public repository.
Open · Testing and approval
A running clinical-hold log
A public table of every clinical hold, an FDA order that stops a trial, placed on a cell or gene therapy trial since 2020, as disclosed in company filings and press releases. Each row gives the product type, the dates the hold was placed and lifted, the stated reason (patient harm, manufacturing, animal data) and the quoted sentence it came from. The table refreshes monthly.
Built with what exists
The US Securities and Exchange Commission's EDGAR full-text search to find "clinical hold" in company filings; company press-release pages; an AI model such as Claude to pull dates and reasons with the quoted sentence; a person checking each row; a CSV file in a public GitHub repository. The note "Findings that cite notes" (Cursor's agent kit) covers an agent built to cite the source behind each finding.
